Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02702388
Title Phase 2 Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 20 mg or 14 mg Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Eisai Inc.
Indications

thyroid gland papillary carcinoma

thyroid gland follicular carcinoma

Therapies

Lenvatinib

Age Groups: adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL


No variant requirements are available.